Researchers developed a new nano-micelle formulation, CBD-IN, that finally gets CBD into the brain effectively. In mice, it relieved neuropathic pain quickly and didn’t cause the usual movement or memory side effects. Surprisingly, the pain relief didn’t use typical cannabinoid receptors, instead calming abnormal nerve activity more directly. The findings hint at new avenues for treating chronic pain and neurological diseases.

Scientists found that people who use both cannabis and tobacco show a distinct brain pattern tied to mood and stress regulation. Their scans revealed higher levels of an enzyme that reduces a natural feel-good molecule in the brain. This imbalance may help explain why co-users experience more anxiety and struggle more when quitting.

Almost 20% of packaged foods and beverages in the US contain synthetic dyes, often paired with excessive sugar to attract children. These additives have been linked to behavioral issues, yet remain widespread among major brands like Mars and PepsiCo. Experts criticize the FDA for relying on voluntary reform, contrasting it with Europe’s stricter labeling laws. Growing state-level action offers hope for meaningful change.

Using powerful 7-Tesla brain imaging, researchers mapped how the brainstem manages pain differently across the body. They discovered that distinct regions activate for facial versus limb pain, showing the brain’s built-in precision pain control system. The findings could lead to targeted, non-opioid treatments that use cannabinoid mechanisms instead of opioids, offering safer pain relief options.

Generalized anxiety disorder affects millions, often trapping sufferers in cycles of fear and isolation that conventional medications barely relieve. At UCSF, neuroscientist Jennifer Mitchell is testing a pharmaceutical form of LSD called MM120, which has shown striking results in reducing symptoms by promoting neuroplasticity and easing rigid thought patterns. In clinical trials, a single dose significantly outperformed standard treatments, offering hope to those who have found little relief elsewhere.

GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, and nicotine use. Though more research is needed, scientists believe these drugs could open a powerful new front in addiction therapy.

Colorado researchers discovered that nearly half of tested cannabis flower products exaggerated their THC levels, while concentrates were mostly accurate. The team’s statewide audit revealed potency inconsistencies that could mislead consumers and affect safe dosing. Beyond THC, the study also found that cannabinoids like CBG and CBGA are underreported. The findings may help shape future regulations and improve consumer trust in the growing cannabis market.

A major collaboration between UC San Diego and 23andMe identified genes that shape cannabis use behaviors. The study linked the CADM2 and GRM3 genes to cannabis use and connected these patterns to more than 100 traits across mental and physical health. Researchers say understanding these genetic influences could help prevent cannabis use disorder and guide future therapies.